Lisa Mckerracher

Biography

Dr. Lisa McKerracher is a successful entrepreneur and business executive. She is the Founder and CEO of BioAxone BioSciences, and is a serial entrepreneur with extensive experience in company start-up, preclinical research and clinical development. Dr. McKerracher created BioAxone in 2011, after acquiring all rights to a Phase II biologic drug to treat spinal cord injury. In 2013, BioAxone BioSciences was selected as one of 10 Life Sciences to participate in the prestigious Springboard program for women entrepreneurs leading high growth companies. Dr. Lisa McKerracher is a successful entrepreneur and business executive. She is the Founder and CEO of BioAxone BioSciences, and is a serial entrepreneur with extensive experience in company start-up, preclinical research and clinical development. Dr. McKerracher created BioAxone in 2011, after acquiring all rights to a Phase II biologic drug to treat spinal cord injury. In 2013, BioAxone BioSciences was selected as one of 10 Life Sciences to participate in the prestigious Springboard program for women entrepreneurs leading high growth companies. She has 15 years of experience in academic research and left a tenured position to pursue her passion for drug development. Dr. McKerracher has published more than 60 research articles in leading journals and has edited a book on spinal cord injury. She has over 30 issued patents as Inventor. Currently, Dr. McKerracher is an Adjunct Professor at McGill University, and Scientific Officer for the Canadian Institute of Health Research Proof-of-Principal commercialization grant committee. She is also a member of a National Institute of Neurological Disorders and Stroke (NINDS)/SBIR review committee for the NIH. Dr. McKerracher holds a BSc from McGill University and PhD from York University, and received post-doctoral training at the Worcester Foundation for Experimental Biology (Massachusetts) and McGill University.  

Research Interest

Clinical-state biopharmaceutical company, regenerative therapeutic drugs, axon regeneration and neuronal signaling pathways